Fusion Genomics Corp.
Enabling precision medicine for infectious diseases by developing a single cost-effective test that gives diagnosis and genomic profiles of all human pathogens.
- Stage Prototype Ready
- Industry Biotechnology
- Location Vancouver, BC, Canada
- Currency USD
- Founded July 2013
- Employees 10
- Incorporation Type LLC
- Website fusiongenomics.com
Company Summary
Direct hospitalization costs due to diagnostic failure in the US is estimated at $14B with over 800k people hospitalized and treated with systemic drugs hoping to cure them. Fusion's mission is to enable precision medicine for infectious diseases by developing a pan-pathogen test that identifies all known human pathogens (~1,400) using all types of sample sources (spit, blood, feces, etc.) and provides all needed genomic data for treatment.
Team
-
President and CSOLed the spinoff of FUSION GENOMICS from the BC Cancer Agency where he worked with world-renowned experts in genomics and drug development. Oversees all the scientific aspects of R&D at FUSION and serves as the interface for all collaborators.
-
VP Product DevelopmentHas over 10 years of experience in genomic technologies including leading edge NGS. He was actively involved in developing molecular diagnostic assays in leading labs in Netherlands and Canada. Brian is responsible for the development of Fusion’s new assays.
-
Greg StazykChief Technology OfficerHas over 25 years of experience and served as the IT lead of one of Canada’s largest bioinformatics platforms at the Genome Science Center where he expanded the infrastructure from a few dozen core-machines to over 10,000 in the core cluster in a CAP/CLIA environment.
-
Shing ZhanBioinformatics LeadHe has proven expertise in computational biology, especially in the analysis of NGS data, and in the development of bioinformatics and statistical methodologies with 15 scientific articles in journals such as Science and the American Journal of Human Genetics
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.